PMC:7156805 / 67-568 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"7","span":{"begin":400,"end":408},"obj":"Species"},{"id":"8","span":{"begin":195,"end":204},"obj":"Disease"},{"id":"9","span":{"begin":259,"end":268},"obj":"Disease"},{"id":"10","span":{"begin":293,"end":317},"obj":"Disease"},{"id":"11","span":{"begin":319,"end":327},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"Tax:9606"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:D007239"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:D011565"},{"id":"A10","pred":"tao:has_database_id","subj":"10","obj":"MESH:C000657245"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":195,"end":204},"obj":"Disease"},{"id":"T3","span":{"begin":259,"end":268},"obj":"Disease"},{"id":"T4","span":{"begin":293,"end":317},"obj":"Disease"},{"id":"T5","span":{"begin":319,"end":327},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005083"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":171,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":363,"end":366},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":416,"end":432},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_50846"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":259,"end":268},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0003765"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":0,"end":14},"obj":"Sentence"},{"id":"T3","span":{"begin":15,"end":149},"obj":"Sentence"},{"id":"T4","span":{"begin":150,"end":338},"obj":"Sentence"},{"id":"T5","span":{"begin":339,"end":500},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To the Editor: We read with great interest the Commentary by Lebwohl et al1 recently published in the Journal of the American Academy of Dermatology. The authors provided a pertinent overview of infection risk associated with commonly used biologics to treat psoriasis in light of the current coronavirus disease 2019 (COVID-19) outbreak. We agree that this time has been particularly concerning for patients taking immunomodulators/immunosuppressants who are unsure of their risk for severe disease.\n"}